Musings
  • About
  • Resources
  • Contact
Press enter to begin your search
AcademiaBiotech

The madness of molnupiravir

A contentious vote On Tuesday, an FDA advisory committee ("AdCom") narrowly (13:10) voted in favor…
Jerome Verony
Jerome VeronyDecember 1, 2021
AcademiaBiotechFinance

Refractory Status Epilepticus: Significant new insights and a potential paradigm shift

Artwork by Greg A. Dunn After what you could call a professionally-induced hiatus, I am…
Jerome Verony
Jerome VeronyDecember 4, 2019
Biotech

Initial clinical data suggests KRAS inhibition provides benefit to cancer patients

Wars are won one battle at a time If you follow the cancer space closely,…
Jerome Verony
Jerome VeronyMay 16, 2019
AcademiaBiotech

Nav1.7: a tough nut to crack

  A recently published piece in the journal nature reviews: drug discovery outlines the challenges involved with…
Jerome Verony
Jerome VeronyApril 11, 2019
Academia

Challenging the dogma of statistical significance in the interest of better decision-making

Statistical inference is the perilous but necessary exercise of drawing conclusions from (sometimes very) limited…
Jerome Verony
Jerome VeronyApril 1, 2019
Arts

Book review: ‘La Photographe’

As a student at Paris' SciencesPo, I would occastionally bemoan the seeming absence of, or…
Jerome Verony
Jerome VeronyMarch 19, 2019
Biotech

Intercept’s NASH fibrosis breakthrough and perceptions around commercial viability

Intercept Pharmaceuticals, which develops & commercializes obeticholid acid ('OCA') in several indications, has reported positive…
Jerome Verony
Jerome VeronyMarch 6, 2019
AcademiaBiotech

New findings show LRRK2 may play crucial role in a significant portion of Parkinson’s disease (‘PD’) patients

A small enzyme known as LRRK2 - named after the genes that encode it - appears to…
Jerome Verony
Jerome VeronyJuly 26, 2018

Contact us

Contact form
  • About
  • Resources
  • Contact